Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2015 - 2017)

Aytu Biopharma (AYTU) has 3 years of Non-Current Deffered Revenue data on file, last reported at $1451.0 in Q2 2017.

• Non-Current Deffered Revenue for Q2 2017 came in at $1451.0, down 82.34% year-over-year; the trailing twelve-month figure through Jun 2017 was $1451.0 (down 82.34% YoY), and the FY2017 annual result was $1451.0, down 82.34% from the prior year.
• Non-Current Deffered Revenue eased to $1451.0 in Q2 2017 per AYTU's latest filing, from $3119.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $425893.0 in Q2 2015 and troughed at $1451.0 in Q2 2017.
• A 3-year average of $177669.8 and a median of $8215.0 in 2016 frame the typical range for Non-Current Deffered Revenue.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 82.34% in 2017 and fell as far as 99.14% in 2017.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $383036.0 in 2015, then slumped by 98.75% to $4787.0 in 2016, then plunged by 69.69% to $1451.0 in 2017.
• Business Quant data shows AYTU's Non-Current Deffered Revenue at $1451.0 in Q2 2017, $3119.0 in Q1 2017, and $4787.0 in Q4 2016.